DrugCendR Inc. – Making Anticancer Drugs More Safe and Effective
DrugCendR Inc. is a biopharmaceutical company dedicated to developing next generation cancer therapies that are designed to overcome the barriers of drug delivery to solid tumors. Our novel drug delivery platform is specific for cancerous tumors, and extensive pre-clinical studies have demonstrated the potential for improving efficacy and for reducing the toxicity and side effects typically associated with cancer treatments. The mechanism of action is well understood, increasing the confidence of translating the technology into a clinical breakthrough.
DrugCendR Inc. has initiated Phase I studies with its lead compound CEND-1. The initial target is pancreatic ductal adenocarcinoma, a tumor with a particularly high barrier for drug entry and dismal prognosis. CEND-1 is given in combination with standard-of-care in a Phase 1b / expanded cohort-type layout. This allows a quick trial execution and a possibility of early efficacy readouts. Additional clinical trials (incl. gastric cancer) are in preparation.
Board of Directors
ERKKI RUOSLAHTI, M.D., Ph.D.
TAMBET TEESALU, Ph.D.
KAZUKI N. SUGAHARA, M.D., Ph.D.